Immuneering (NASDAQ:IMRX) Given “Buy” Rating at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRXFree Report) in a research report sent to investors on Wednesday morning,Benzinga reports. Chardan Capital currently has a $13.00 price objective on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Immuneering in a research report on Thursday, November 14th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Immuneering presently has an average rating of “Moderate Buy” and a consensus price target of $12.80.

View Our Latest Research Report on Immuneering

Immuneering Price Performance

NASDAQ:IMRX opened at $2.04 on Wednesday. The business has a fifty day moving average price of $2.21 and a 200-day moving average price of $1.62. Immuneering has a one year low of $1.00 and a one year high of $8.89. The firm has a market capitalization of $63.34 million, a price-to-earnings ratio of -1.04 and a beta of -0.40.

Hedge Funds Weigh In On Immuneering

Several large investors have recently modified their holdings of IMRX. Vontobel Holding Ltd. bought a new position in Immuneering during the third quarter valued at $25,000. Corsair Capital Management L.P. purchased a new position in shares of Immuneering during the 3rd quarter worth about $25,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Immuneering during the 2nd quarter worth about $44,000. XTX Topco Ltd grew its holdings in Immuneering by 37.3% during the 2nd quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after purchasing an additional 9,274 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Immuneering in the 2nd quarter worth about $67,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

(Get Free Report)

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.

Featured Articles

Analyst Recommendations for Immuneering (NASDAQ:IMRX)

Receive News & Ratings for Immuneering Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuneering and related companies with MarketBeat.com's FREE daily email newsletter.